APA

Ma M. H., Yang H. H., Parker K., Manyak S., Friedman J. M., Altamirano C., Wu Z., Borad M. J., Frantzen M., Roussos E., Neeser J., Mikail A., Adams J., Sjak-Shie N., Vescio R. A. & Berenson J. R. (20031003). The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Ma Mark H, Yang Hank H, Parker Kimberly, Manyak Steven, Friedman Jeffrey M, Altamirano Cibby, Wu Zhi-qun, Borad Mitesh J, Frantzen Malka, Roussos Evanthia, Neeser Jason, Mikail Amy, Adams Julian, Sjak-Shie Nelida, Vescio Robert A and Berenson James R. 20031003. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Ma M. H., Yang H. H., Parker K., Manyak S., Friedman J. M., Altamirano C., Wu Z., Borad M. J., Frantzen M., Roussos E., Neeser J., Mikail A., Adams J., Sjak-Shie N., Vescio R. A. and Berenson J. R. (20031003). The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Ma Mark H, Yang Hank H, Parker Kimberly, Manyak Steven, Friedman Jeffrey M, Altamirano Cibby, Wu Zhi-qun, Borad Mitesh J, Frantzen Malka, Roussos Evanthia, Neeser Jason, Mikail Amy, Adams Julian, Sjak-Shie Nelida, Vescio Robert A and Berenson James R. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20031003.